2023-09-03 12:00:00 ET
More on Medicare pricing negotiations
- Wall Street lists potential targets for Medicare drug price negotiations
- Analysts rule out major industry impact from drug pricing negotiations
- J&J, Merck, Regeneron most exposed to Medicare drug price negotiation - Bloomberg
- Medicare revises guidance on drug price negotiations amid lawsuits
- US Chamber of Commerce sues US government over drug pricing program
- Merck sues US Government to halt Medicare drug pricing program
For further details see:
Why is big pharma unmoved despite Medicare pricing threat?